Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.
- DOI
- 10.1038/s41591-026-04476-6
- Published
- 2026 Aug
- Container
- Nature medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41591-026-04476-6,
title = {Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.},
author = {Rosenstock J and Lingvay I and Ryan D and Jastreboff AM and Kushner R and Acosta A and Blevins TC and Choi M and Holmes FL and Smith T and Connery L and Li Y and Liu MK and Barth A and Butcher J and Civitarese A and Yue H and Coll B and ACCESS Trial Investigators},
year = {2026},
journal = {Nature medicine},
doi = {10.1038/s41591-026-04476-6},
url = {https://doi.org/10.1038/s41591-026-04476-6}
}RIS
TY - JOUR TI - Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. AU - Rosenstock J AU - Lingvay I AU - Ryan D AU - Jastreboff AM AU - Kushner R AU - Acosta A AU - Blevins TC AU - Choi M AU - Holmes FL AU - Smith T AU - Connery L AU - Li Y AU - Liu MK AU - Barth A AU - Butcher J AU - Civitarese A AU - Yue H AU - Coll B AU - ACCESS Trial Investigators PY - 2026 JO - Nature medicine DO - 10.1038/s41591-026-04476-6 UR - https://doi.org/10.1038/s41591-026-04476-6 ER -
APA
J, R., I, L., D, R., AM, J., R, K., A, A., TC, B., M, C., FL, H., T, S., L, C., Y, L., MK, L., A, B., J, B., A, C., H, Y., B, C., & Investigators, A. T. (2026). Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.. Nature medicine. https://doi.org/10.1038/s41591-026-04476-6
Source records
- pubmed · retrieved 2026-09-27T13:10:10.798Z